<DOC>
	<DOCNO>NCT01829113</DOCNO>
	<brief_summary>This randomized phase II study compare efficacy safety combination carboplatin pemetrexed without OGX-427 patient previously untreated advanced non-squamous NSCLC .</brief_summary>
	<brief_title>Phase II Trial Carboplatin Pemetrexed +/- OGX-427 Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis advance NSCLC , exclude squamous cell small cell histology . Tumors mixed NSCLC histology eligible , long predominant histology squamous . If smallcell element present otherwise specify histologically , patient eligible . 2 . Metastatic disease ( accord American Joint Committee Cancer ( AJCC ) stag system , v7.0 ) . 3 . No prior systemic chemotherapy , immunotherapy , target therapy , biological therapy metastatic disease ; adjuvant neoadjuvant therapy Stage I , II , III disease allow long interval end treatment disease progression &gt; 12 month . 4 . No prior radiation therapy whole pelvis ≥25 % total bone marrow area . Other radiation therapy must complete least 2 week prior study entry . Must recover acute adverse effect prior study entry . 5 . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . 7 . Baseline laboratory value follow : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥10 g/dL Platelets ≥100,000/μL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , ≤3.0 x upper limit normal ( ULN ) ; 5 x ULN know hepatic metastasis . Total bilirubin ≤1.5 x ULN , unless secondary Gilbert 's disease Serum creatinine ≤1.5 x ULN . If creatinine &gt; 1.5 , calculate creatinine clearance ( CrCl ) ≥45 mL/min CockcroftGault method : Glomerular Filtration Rate ( GFR ) = ( 140age ) x ( weight/kg ) x ( 0.85 female ) / ( 72 x serum creatinine mg/dL ) 8 . Fertile male patient willing use adequate contraceptive measure . 9 . Female patient childbearing potential , fertile female patient childbearing potential agree use adequate contraceptive measure , breastfeeding , negative serum urine pregnancy test within 72 hour prior start randomization . 10 . Life expectancy ≥ 12 week . 11 . Must ≥18 year age time consent . 12 . Willingness ability comply trial followup procedure . 13 . Ability understand nature trial give write informed consent . 1 . Known anaplastic lymphoma kinase ( ALK ) translocation epidermal growth factor receptor ( EGFR ) `` activate '' mutation firstline treatment target tyrosine kinase inhibitor therapy appropriate . 2 . Known central nervous system ( CNS ) disease neurologically stable , treated brain metastasis define metastasis evidence progression hemorrhage treatment ongoing requirement corticosteroid , ( e.g. , dexamethasone ) least 2 week . 3 . Any following cardiac disease currently within last 6 month define New York Heart Association ( NYHA ) ≥ Class 2 : Unstable angina pectoris Congestive heart failure Acute myocardial infarction Conduction abnormality control pacemaker medication Significant ventricular supraventricular arrhythmia ( Patients chronic ratecontrolled atrial fibrillation absence cardiac abnormality eligible ) . 4 . Patients currently receive therapeutic anticoagulation . 5 . Pregnant lactating woman . 6 . Any serious , active underlie medical condition would impair ability patient receive study treatment , diabetes mellitus infection . 7 . Unable unwilling take folic acid vitamin B12 . 8 . Active second malignancy ( except nonmelanomatous skin superficial bladder cancer ) define require current need cancer therapy high risk recurrence study . 9 . Psychological , familial , sociological , geographical condition permit compliance protocol . 10 . Inability unwillingness comply trial and/or followup procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Recurrent Lung Cancer</keyword>
	<keyword>Stage IV Lung Cancer</keyword>
	<keyword>OGX-427</keyword>
	<keyword>Sarah Cannon Research Institute</keyword>
	<keyword>SCRI</keyword>
	<keyword>OncoGenex</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
</DOC>